Publications by authors named "Eric Mangin"

Claim this Profile
A
A population pharmacokinetic model for posaconazole intravenous solution and oral powder for suspension formulations in pediatric patients with neutropenia.
Gregory Winchell, Rik de Greef, Aziz Ouerdani, Floris Fauchet, Rebecca E Wrishko, Eric Mangin

Antimicrob Agents Chemother· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning.
Hubert Bland, Xiaodong Li, Eric Mangin, Ka Lai Yee, Christopher Lines

J Clin Psychopharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial.
Andreas H Groll, Hisham Abdel-Azim, Thomas Lehrnbecher, William J Steinbach, Amanda Paschke, Eric Mangin

Int J Antimicrob Agents· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fine-Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection.
Wei Gao, Andrea L Webber, Jill Maxwell, Melanie Anderson, Luzelena Caro, Eric Mangin

Clin Pharmacol Ther· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.
Kaiyan Liu, Depei Wu, Junmin Li, Hu Chen, Hongmei Ning, Eric Mangin

Adv Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
Antonio C Arrieta, Lillian Sung, John S Bradley, C Michel Zwaan, Davis Gates, Eric Mangin

PLoS One· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
Haiyan Li, Yudong Wei, Shuang Zhang, Lin Xu, Jun Jiang, Eric Mangin

Clin Drug Investig· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
Hwa-Ping Feng, Zifang Guo, Luzelena Caro, Jennifer E Talaty, Eric Mangin

Clin Pharmacol Drug Dev· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Rebecca E Wrishko, Jacqueline B McCrea, Ka Lai Yee, Wen Liu, Deborah Panebianco, Eric Mangin

Clin Drug Investig· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Rebecca E Wrishko, Jacqueline B McCrea, Ka Lai Yee, Wen Liu, Deborah Panebianco, Eric Mangin

Clin Drug Investig· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
Hwa-Ping Feng, Zifang Guo, Lisa L Ross, Iain Fraser, Deborah Panebianco, Eric Mangin

J Antimicrob Chemother· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum for Rhee et al., "Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants".
Elizabeth G Rhee, Matthew L Rizk, Nicole Calder, Marcela Nefliu, Steven J Warrington, Eric Mangin

Antimicrob Agents Chemother· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Odanacatib Pharmacokinetics Comparison Between Chinese and Non-Chinese Postmenopausal Women.
Xia Chen, Ji Jiang, Pei Hu, Stefan Zajic, Wen Liu, Eric Mangin

Clin Pharmacol Drug Dev· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.
Elizabeth G Rhee, Matthew L Rizk, Nicole Calder, Marcela Nefliu, Steven J Warrington, Eric Mangin

Antimicrob Agents Chemother· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
Matthew L Rizk, Elizabeth G Rhee, Patricia A Jumes, Mark H Gotfried, Tian Zhao, Eric Mangin

Antimicrob Agents Chemother· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
William L Marshall, Hwa-Ping Feng, Luzelena Caro, Jennifer Talaty, Zifang Guo, Eric Mangin

Eur J Clin Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.
Hong Sun, Ka Lai Yee, Sean Gill, Wen Liu, Xiaodong Li, Eric Mangin

J Psychopharmacol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.
Hong Sun, William P Kennedy, Darren Wilbraham, Nicole Lewis, Nicole Calder, Eric Mangin

Sleep· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir.
William D Hanley, Larissa A Wenning, Allison Moreau, James T Kost, Eric Mangin

Antimicrob Agents Chemother· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
Larissa A Wenning, William D Hanley, Diana M Brainard, Amelia S Petry, Kalyan Ghosh, Eric Mangin

Antimicrob Agents Chemother· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
Marian Iwamoto, Larissa A Wenning, Amelia S Petry, Martine Laethem, Marina De Smet, Eric C Mangin

Antimicrob Agents Chemother· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.
Marian Iwamoto, Kelem Kassahun, Matthew D Troyer, William D Hanley, Ping Lu, Eric Mangin

J Clin Pharmacol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis